Rich Horgan believes that there’s an alternative path to drug development that can lower costs and the time it takes to bring drugs to market. He is trying to apply it to the field of rare and ultra-rare diseases.

California passed a law last year aimed at controlling rising healthcare costs that gave the state the ability to scrutinize healthcare deals of a certain size involving California companies. What impact can it have?

The founder and CEO of Unlearn.AI seeks to make clinical trials more efficient and less costly by leveraging its Digital Twin technology. If the company is successful, drugs could potentially be brought to market sooner and in a cost effective manner.

Pharmaceutical manufacturers say high U.S. prices support research and development and point out that Americans tend to get new treatments first. But recent research has shown that the price of a drug is related neither to the amount of research and development required to bring it to market nor its therapeutic value.

Transformations in the Life Sciences is the focus of the second season of the MedCity Pivot Podcast. My personal journey as a caregiver of a cancer patient made me choose Dr. Sumanta Pal, co-director of the City of Hope’s Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet.

New York Governor Kathy Hochul signed new legislation that will protect the state’s doctors, medical providers and facilitators who prescribe abortion care telehealth services to patients outside of New York from litigation in states where abortion services are banned or restricted.

I interview Punit Singh Soni, CEO of Suki and Niall O’Connor, CTO, Cohere Health to evaluate two areas where AI can have an outsize impact: clinical documentation and prior authorization.

In an environment where capital isn’t as easy to access, INVEST Digital Health conference will seek to arm you with the right connections and meaningful insight to navigate an environment where ROI is king. Hear from payers, providers, startups, life sciences executives, VCs and more.

A conversation with Suchi Saria, associate professor of medicine at John Hopkins University and director of its Machine Learning and Healthcare Lab about responsible AI.

The quest to enact local bans has become particularly acute in small towns, like West Wendover, Nevada, and Hobbs, New Mexico, which are situated by borders between states that have restricted abortion and states where laws preserve access.

In a wide-ranging interview, Sanford Health’s president of virtual care explained how virtual care may be well suited to rural populations.

The law creates a crime of “abortion trafficking” and criminalizes the “recruiting, harboring, or transporting” of minors without parental consent

Season 2 of our MedCity Pivot Podcast launches today with a conversation about how AI can be leveraged to transform precision medicine.

Competition to claim a market that could be worth $100 billion a year for drugmakers alone has triggered a wave of advertising that has provoked the concern of regulators and doctors worldwide.

In a recent interview, Dr. Jesse Ehrenfeld, the president-elect at the American Medical Association, outlined how the major pain point of physicians has gone from the EHR to prior authorizations requests. But none of the individual efforts that payers are making is enough.

Paris-based Sofinnova Partners announced last week that it has launched a new strategy aimed at investing in a new breed of startups that straddle the lines between data and biology.

Paul Markovich believes in the value of health tech in managing both chronic diseases and in general health and wellness. In this episode, he talks about the company’s Wellvolution platform and the digital tools that are offered there to members, now even to those on Medicaid.

In an interview at the Vive conference in Nashville, Tennessee, Craig Richardville, Intermountain’s chief digital and information officer outlined the three areas of priority for Intermountain Health for which technology can be leveraged. But when it comes to a major headache for CIOs, Richardville seems to suggest that a government-led all-hands-on-deck approach is what is needed.

Included Health CEO Owen Tripp believes that the sudden demise of Silicon Valley Bank may actually lead to a “culling of the herd” as healthtech companies yet to prove their value will stop functioning as standalone companies or get bought by larger companies with stable revenue and a proven business model.

Some actions to reduce healthcare’s carbon footprint actually will save money, said Jonathan Perlin, CEO of the nonprofit national and international accrediting organization.

Steve Driver is an interventional cardiologist as well as medical director of digital therapeutics at Advocate Aurora Health, which last year merged with Atrium Health. In this episode, he talked about a pilot involving Omada Health targeting a prediabetes population, among other things.

The largest six pharmacy benefit managers are being scrutinized by the Federal Trade Commission, while Congress is debating the Pharmacy Benefit Transparency Act. Meanwhile, states have their own ideas for reining in what they see as excesses of the industry. With all this heat, what is the message from the head of the Pharmaceutical Care Management Association?

A new treatment under development by HeartPoint Global seeks to provide a minimally invasive and cheaper alternative to current treatments for pulmonary arterial hypertension.

Season one focusing on chronic disease management kicks off with a conversation with Stephanie Tilenius, CEO of Vida Health that aims to treat both the mind and the body.

Was Livongo a good business? As Burke, now CEO of Quantum Health, touts its strength to investors ahead of a potential IPO, should the Livongo-Teladoc history give them pause?

The healthcare navigation market — especially companies targeting self-insured employers — is fairly crowded. You […]

The 41st annual J.P. Morgan Healthcare Conference concluded last week. After the pandemic prompted it to go virtual, it was back in person, smaller in size and more effective. Here are my takeaways.

A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.

Reporters are pitched endlessly about companies they need to meet at this annual healthcare conference and the ecosystem it has sprung. These companies stood out to me and they play in the biopharma, devices, diagnostics and health tech worlds.

In a media briefing during the J.P. Morgan Healthcare Conference in San Francisco, Paul Hudson said unlike Sanofi, large pharma companies with top-selling drugs have a portfolio akin to a leaky bathtub because in a few years, they will have to replace much of that revenue as drug patents expire.